{"url_path":"/sec/imdx/8-k/2026-05-13/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1642380/0001493152-26-022721-index.html","accession_number":"0001493152-26-022721","cik":"0001642380","ticker":"IMDX","issuer_name":"Insight Molecular Diagnostics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1642380/0001493152-26-022721-index.html","primary_entity_key":"0001642380","primary_entity_name":"Insight Molecular Diagnostics Inc."},"word_count":168,"has_tables":true,"body_markdown":"**Item\n2.02 Results of Operations and Financial Condition.**\n\n \n\nOn\nMay 13, 2026, Insight Molecular Diagnostics Inc. (“we,” “us,” “our,” the “Company” or\n“iMDx”) issued a press release announcing our financial results for the three months ended March 31, 2026. A copy of the\npress release is furnished as Exhibit 99.1, which, in its entirety, is incorporated herein by reference.\n\n \n\nThe\ninformation in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, is being furnished and shall not be\ndeemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),\nor otherwise subject to the liabilities of that section. Such information shall not be deemed incorporated by reference into any filing\nof the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless\nof any general incorporation language in such filing, except as otherwise expressly set forth by specific reference in such filing."}